GlobeNewswire: Colibri Heart Valve LLC Contains the last 10 of 23 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T09:14:24ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/11/03/2326691/0/en/Colibri-Heart-Valve-Initiates-International-CE-Mark-enabling-Pilot-Study-of-Second-Generation-TAVI-System.html?f=22&fvtc=4&fvtv=14371Colibri Heart Valve Initiates International CE Mark-enabling Pilot Study of Second-Generation TAVI System 2021-11-03T15:52:40Z<![CDATA[LOUISVILLE, CO , Nov. 03, 2021 (GLOBE NEWSWIRE) -- Colibri Heart Valve LLC, a privately held emerging medical device company, today announced the initiation of an international pilot study of the Colibri transcatheter aortic valve implantation (TAVI) system. Bernard Chevalier, M.D., an interventional cardiologist at Hôpital Privé Jacques Cartier, is serving as primary investigator of the study. The study involves enrolling patients with severe aortic stenosis who are at high surgical risk. The first patients treated in this pilot study were enrolled in Toulouse, France. Additional study sites are expected to open later this year in the UK.]]>https://www.globenewswire.com/news-release/2019/09/24/1920278/0/en/Colibri-Heart-Valve-Receives-a-United-States-Patent-Directed-to-a-Replacement-Heart-Valve-that-Includes-a-Dry-Valve-Sutured-to-a-Stent-Member.html?f=22&fvtc=4&fvtv=14371Colibri Heart Valve Receives a United States Patent Directed to a Replacement Heart Valve that Includes a Dry Valve Sutured to a Stent Member 2019-09-24T20:01:20Z<![CDATA[BROOMFIELD, CO, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Colibri Heart Valve LLC, a privately held emerging medical device company, today announced that U.S. Patent No. 10,390,945 (“the ‘945 Patent”) was issued on August 27, 2019 by the United States Patent & Trademark Office with a priority date extending back to July 2004. The ‘945 Patent has a total of ten claims, including a claim directed to a replacement heart valve that comprises a stent member and a dry valve of treated pericardium sutured to the stent member. The ‘945 Patent further includes an assembly claim that comprises a delivery and implantation system with a replacement heart valve residing within the delivery and implantation system.]]>https://www.globenewswire.com/news-release/2019/05/14/1823841/0/en/Colibri-Heart-Valve-to-Present-One-Year-Patient-Follow-Up-Results-from-Clinical-Feasibility-Study-of-Second-Generation-TAVI-System-at-EuroPCR.html?f=22&fvtc=4&fvtv=14371Colibri Heart Valve to Present One-Year Patient Follow-Up Results from Clinical Feasibility Study of Second-Generation TAVI System at EuroPCR2019-05-14T14:00:00Z<![CDATA[BROOMFIELD, CO , May 14, 2019 (GLOBE NEWSWIRE) -- Colibri Heart Valve LLC, a privately held emerging medical device company, today announced that results from the company’s international, single-arm, open-label early feasibility study (EFS) of the Colibri transcatheter aortic valve implantation (TAVI) system will be presented at the upcoming EuroPCR annual meeting taking place May 21-24, 2019. One-year follow-up data from the five evaluable patients, two of whom received a 27mm valve and three a 24mm valve, will be presented by R. David Fish, MD, FACC, FSCAI, Colibri’s founder and chief medical officer, on May 23rd in Room 353. Details will also be available at the Colibri exhibit booth #M15.]]>https://www.globenewswire.com/news-release/2018/09/19/1573325/0/en/Colibri-Heart-Valve-to-Present-Patient-Follow-up-Results-from-Clinical-Feasibility-Study-of-Second-Generation-TAVI-System-at-TCT.html?f=22&fvtc=4&fvtv=14371Colibri Heart Valve to Present Patient Follow-up Results from Clinical Feasibility Study of Second-Generation TAVI System at TCT2018-09-19T18:12:08Z<![CDATA[BROOMFIELD, CO , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Colibri Heart Valve LLC, a privately held emerging medical device company, today announced that results from the company’s international, single-arm, open-label early feasibility study (EFS) of the Colibri transcatheter aortic valve implantation (TAVI) system will be presented at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) annual meeting taking place September 21-25, 2018 in San Diego, CA. Follow-up data from the five evaluable patients, two of whom received a 27mm valve and three a 24mm valve, will be presented by R. David Fish, MD, FACC, FSCAI, Colibri’s founder and chief medical officer. Details may also be available at the Colibri exhibit booth #2148.]]>https://www.globenewswire.com/news-release/2018/05/04/1496922/0/en/Colibri-Heart-Valve-Continues-Enrollment-in-Clinical-Feasibility-Study-of-Second-Generation-TAVI-System.html?f=22&fvtc=4&fvtv=14371Colibri Heart Valve Continues Enrollment in Clinical Feasibility Study of Second-Generation TAVI System 2018-05-04T15:09:01Z<![CDATA[EuroPCR Exhibit will Highlight Package-to-Patient Design EuroPCR Exhibit will Highlight Package-to-Patient Design]]>https://www.globenewswire.com/news-release/2018/03/19/1442176/0/en/Colibri-Heart-Valve-Advances-Second-Generation-TAVI-System-into-Clinical-Feasibility-Study.html?f=22&fvtc=4&fvtv=14371Colibri Heart Valve Advances Second-Generation TAVI System into Clinical Feasibility Study2018-03-19T14:52:42Z<![CDATA[BROOMFIELD, CO , March 19, 2018 (GLOBE NEWSWIRE) -- Colibri Heart Valve LLC, a privately held emerging medical device company, today announced that the first two patients have been successfully enrolled in a clinical early feasibility study (EFS) of the company’s disruptive second-generation ready-for-use balloon-expandable transcatheter aortic valve implantation (TAVI) system. As with Colibri’s earlier generation system, this TAVI system contains a replacement aortic heart valve that is pre-mounted, and pre-crimped on a balloon delivery catheter, loaded into a low-profile access sheath and sterilized, ready-for-use from package to patient. The company’s second-generation TAVI system includes enhancements to address a wider range of patient candidates including those with bicuspid aortic valves.]]>https://www.globenewswire.com/news-release/2017/03/03/931391/0/en/Colibri-Heart-Valve-Receives-ISO-13485-and-EN-ISO-13485-Certification.html?f=22&fvtc=4&fvtv=14371Colibri Heart Valve Receives ISO 13485 and EN ISO 13485 Certification 2017-03-03T15:00:00Z<![CDATA[BROOMFIELD, CO , March 03, 2017 (GLOBE NEWSWIRE) -- Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, announced today that it has received certification from DEKRA Certification B.V. that the company complies with the European requirements of ISO 13485 and EN ISO 13485 for a comprehensive quality management system for the design and manufacture of the company’s pre-packaged, ready-for-use, transcatheter aortic heart valve implantation (TAVI) system.]]>https://www.globenewswire.com/news-release/2016/09/13/871464/0/en/Colibri-Heart-Valve-Enters-Agreement-with-Venus-Medtech-to-Form-Joint-Venture-to-Develop-Next-Generation-Transcatheter-Heart-Valve-Technologies.html?f=22&fvtc=4&fvtv=14371Colibri Heart Valve Enters Agreement with Venus Medtech to Form Joint Venture to Develop Next-Generation Transcatheter Heart Valve Technologies 2016-09-13T12:00:00Z<![CDATA[Colibri Closes Series C Financing with Venus Medtech Investment Colibri Closes Series C Financing with Venus Medtech Investment]]>https://www.globenewswire.com/news-release/2016/04/27/833452/0/en/Colibri-Heart-Valve-Receives-European-Patent-for-a-Method-of-Making-a-Pre-packaged-Sterilized-Dry-Heart-Valve-Pre-mounted-on-a-Delivery-Catheter.html?f=22&fvtc=4&fvtv=14371Colibri Heart Valve Receives European Patent for a Method of Making a Pre-packaged, Sterilized Dry Heart Valve, Pre-mounted on a Delivery Catheter2016-04-27T12:00:00Z<![CDATA[BROOMFIELD, CO , April 27, 2016 (GLOBE NEWSWIRE) -- Colibri Heart Valve LLC, a privately held emerging medical device company, has received notification from the European Patent Office that patent application No. 11751242.6 titled, “Percutaneously Deliverable Heart Valve and Methods Associated Therewith” has been granted and is expected to publish as European Patent No. 2542184 (the “European Patent”) on May 25, 2016. This European Patent is directed towards a method of making a pre-packaged, sterilized dry heart valve mounted on a delivery catheter and has priority claims dating back to March 1, 2010. This European Patent is a significant addition to Colibri’s intellectual property (IP) portfolio in the field of a pre-packaged ready-for-use transcatheter heart valve (THV) mounted on a delivery system, and represents the 15th Colibri patent allowed/granted to date.]]>https://www.globenewswire.com/news-release/2016/02/25/814331/0/en/Colibri-Heart-Valve-Forms-a-New-Entity-to-Monetize-Tissue-Processing-Technology-in-Applications-Outside-of-Structural-Heart.html?f=22&fvtc=4&fvtv=14371Colibri Heart Valve Forms a New Entity to Monetize Tissue Processing Technology in Applications Outside of Structural Heart 2016-02-25T20:00:00Z<![CDATA[Colibri Converts Sr. Secured Notes and Opens Series C Financing Colibri Converts Sr. Secured Notes and Opens Series C Financing]]>